Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Income from Continuing Operations: 2010-2025

Historic Income from Continuing Operations for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to -$3.4 million.

  • Lineage Cell Therapeutics' Income from Continuing Operations fell 13.96% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.0 million, marking a year-over-year decrease of 59.75%. This contributed to the annual value of -$18.6 million for FY2024, which is 13.49% up from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Income from Continuing Operations is -$3.4 million, which was up 82.30% from -$19.3 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Income from Continuing Operations' 5-year high stood at -$1.4 million during Q1 2021, with a 5-year trough of -$28.0 million in Q4 2021.
  • Its 3-year average for Income from Continuing Operations is -$6.3 million, with a median of -$5.2 million in 2023.
  • The largest annual percentage gain for Lineage Cell Therapeutics' Income from Continuing Operations in the last 5 years was 82.82% (2021), contrasted with its biggest fall of 2,946.44% (2021).
  • Lineage Cell Therapeutics' Income from Continuing Operations (Quarterly) stood at -$28.0 million in 2021, then soared by 77.29% to -$6.4 million in 2022, then grew by 25.90% to -$4.7 million in 2023, then surged by 31.06% to -$3.2 million in 2024, then dropped by 13.96% to -$3.4 million in 2025.
  • Its last three reported values are -$3.4 million in Q3 2025, -$19.3 million for Q2 2025, and -$6.0 million during Q1 2025.